 DALLAS, Aug. 11, 2021 PRNewswire -- Lantern Pharma NASDAQ: LTRN, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence A.I. platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration FDA has granted LP-184 Orphan Drug Designation for the treatment of pancreatic cancer. 